Kaiserslautern, Germany

Andrea Thommet

This inventor holds 1 USPTO granted patent. Top assignee: Faustus Forschungs Cie, Translational Cancer Research Gmbh. Active years: 2006.


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andrea Thommet: Innovator in Cancer Treatment

Introduction

Andrea Thommet is a notable inventor based in Kaiserslautern, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds for cancer treatment. His work focuses on creating innovative solutions that can potentially improve patient outcomes in oncology.

Latest Patents

Andrea Thommet holds a patent for "Indigoid bisindole derivatives." This invention relates to novel indigoid bisindole derivatives that can be utilized in the manufacture of a medicament for the treatment of solid cancers. This patent highlights his commitment to advancing cancer therapies through innovative chemical compounds.

Career Highlights

Thommet is associated with Faustus Forschungs Cie, Translational Cancer Research GmbH, where he applies his expertise in medicinal chemistry. His role in this organization allows him to collaborate with other professionals in the field and contribute to groundbreaking research aimed at combating cancer.

Collaborations

Some of his notable coworkers include Gerhard Eisenbrand and Doris Marko. Their collaboration fosters a dynamic research environment that encourages the exchange of ideas and expertise, ultimately leading to advancements in cancer treatment.

Conclusion

Andrea Thommet's work exemplifies the impact of innovation in the medical field, particularly in the fight against cancer. His contributions through patents and collaboration with esteemed colleagues underscore the importance of research in developing effective treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…